Pakistan all set to begin local vaccine production from next month
The National Institute of Health has announced that Pakistan will start the local production of CanSinoBio’s coronavirus vaccine in May.
The NIH officials stated that the arrangements to prepare the CanSinoBio’s coronavirus vaccine have been made, while the raw material for the vaccine would reach Pakistan next month.
Chinese experts are also currently in Islamabad to help prepare the vaccine, officials said, adding the NIH had begun the trial in collaboration with a Chinese company.
Known as Ad5-nCoV, CanSinoBIO developed the Coronavirus vaccine in association with the Beijing Institute of Biotechnology. The vaccine was tested in large-scale phase-III clinical trials held in five countries, including Pakistan, in which more than 40,000 volunteers participated.
The trial results were published earlier this year which confirmed that the CanSinoBIO vaccine was 65% effective at preventing symptomatic cases and 91% effective at preventing severe infection.
As for the Pakistani subset, the vaccine offered 75% protection against symptomatic cases and 100% protection against severe infection.
Moreover, no serious safety concerns and side-effects of the CanSinoBIO vaccine were reported during the multination clinical trials.
In February this year, the Drug Regulatory Authority of Pakistan (DRAP) granted Emergency Use Authorization (EUA) to CanSinoBIO’s COVID-19 vaccine.
What are your views on this? Share with us in the comments below.